- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response - - Data represent the first demonstration of PROTAC ®-mediated degradation ...
NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback